WHO listed the COVID-19 vaccine by Johnson & Johnson for use and booked 500 million doses of the vaccine

15.03.2021 12:19

TASHKENT, March 15. /“Dunyo” IA/. The World Health Organization (WHO) today listed the COVID-19 vaccine, developed by Janssen (Johnson & Johnson), for emergency use in all countries and COVAX roll-out, reports “Dunyo” IA correspondent.

WHO Director-General, Dr. Tedros Adhanom Ghebreyesus said that the COVAX Facility has booked 500 million doses of the vaccine.

According to WHO, the vaccine from Janssen is the first to be listed by WHO as a single dose regimen, which should facilitate vaccination logistics in all countries. The ample data from large clinical trials shared by the company also shows that the vaccine is effective in older populations.

To expedite the listing of the vaccine, WHO and a team of assessors from all regions adopted what is called an ‘abbreviated assessment’ based on outcomes of the EMA review, and evaluation of quality, safety and efficacy data focused on low- and the middle-income country needs. The WHO assessment also considered suitability requirements such as cold chain storage and risk management plans to be implemented in countries.

While the vaccine needs to be stored at -20 degrees, which may prove challenging in some environments, it can be kept for three months at 2-8°C and it has a long shelf life of two years.

WHO will convene its Strategic Advisory Group on Immunization Experts next week to formulate recommendations on the use of the vaccine. In the meantime, WHO continues to work with countries and COVAX partners to prepare for roll-out and safety monitoring. 

WHO has also listed the Pfizer/BioNTech, Astrazeneca-SK Bio and Serum Institute of India vaccines for emergency use.

Online Maslahat

Ism

E-mail

Maslahat

Useful links

booked.net
booked.net